## Shuyan Liu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5235194/publications.pdf

Version: 2024-02-01

1163117 1281871 11 329 8 11 citations h-index g-index papers 11 11 11 497 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects. Journal of Experimental and Clinical Cancer Research, 2018, 37, 261.	8.6	112
2	Cholesterol content in cell membrane maintains surface levels of ErbB2 and confers a therapeutic vulnerability in ErbB2-positive breast cancer. Cell Communication and Signaling, 2019, 17, 15.	6.5	66
3	The deubiquitylase USP2 maintains ErbB2 abundance via counteracting endocytic degradation and represents a therapeutic target in ErbB2-positive breast cancer. Cell Death and Differentiation, 2020, 27, 2710-2725.	11.2	28
4	Amplification of USP13 drives non-small cell lung cancer progression mediated by AKT/MAPK signaling. Biomedicine and Pharmacotherapy, 2019, 114, 108831.	5.6	27
5	USP42 drives nuclear speckle mRNA splicing via directing dynamic phase separation to promote tumorigenesis. Cell Death and Differentiation, 2021, 28, 2482-2498.	11.2	26
6	USP29 enhances chemotherapy-induced stemness in non-small cell lung cancer via stabilizing Snail1 in response to oxidative stress. Cell Death and Disease, 2020, 11, 796.	6.3	22
7	The exon 19-deleted EGFR undergoes ubiquitylation-mediated endocytic degradation via dynamin activity-dependent and -independent mechanisms. Cell Communication and Signaling, 2018, 16, 40.	6.5	17
8	The Anticancer Potential of Apigenin Via Immunoregulation. Current Pharmaceutical Design, 2021, 27, 479-489.	1.9	16
9	Dynasore-induced potent ubiquitylation of the exon 19 deletion mutant of epidermal growth factor receptor suppresses cell growth and migration in non-small cell lung cancer. International Journal of Biochemistry and Cell Biology, 2018, 105, 1-12.	2.8	8
10	Dynasore potentiates c-Met inhibitors against hepatocellular carcinoma through destabilizing c-Met. Archives of Biochemistry and Biophysics, 2020, 680, 108239.	3.0	6
11	Endocytic degradation of ErbB2 mediates the effectiveness of neratinib in the suppression of ErbB2-positive ovarian cancer. International Journal of Biochemistry and Cell Biology, 2019, 117, 105640.	2.8	1